+ Watch PSTI
on My Watchlist
A couple of weeks ago Pluristem announced that results of their phase I/II trial of PLX placental stem cell soup in gluteal muscle injury after hip replacement would be announced this coming Tuesday. That PR was immediately followed by a breathless Seeking Alpha article from frequent Pluristem cheerleader Sharon di Stefano. Traders who bought in anticipation of a run-up to data got a 10% bump for their efforts. Not bad, I guess, but not great considering the performance of IBB and other biopharams in the winter froth and frenzy in the biopharma sector. I'm not sure how the data will turn out, given the fact that the trial is randomized and placebo-controlled. That will make it substantially harder for Pluristem to distill some positive findings from the trial if PLX cells are as inert as I suspect. On the other hand, if allogeneic placental soup is a good thing for injured butts then this pick will be ravaged for quite some time to come.
the stock its in her lower price and other company with the same prodact without any life saver like psti the stoock need to be like 7-8 dollars
Their technology seems to work. PLX-PAD is the only drug that heals the heart muscle instead of just prolonging life. Their drug for aplastic anaemia has been given to two people in a tel aviv hospital under Israel's compassion rule for terminal patients and both have survived. Looks like exciting work in their "snake oil". People seem to be scared of any new technology and will wait until they have a product on the market, missing the big run up (or down) during the development.
biotech has not been as tied to broad market ups and downs.It is tied to the performance of it's product. PSTI has a productwhich has MANY uses,not a one trick poney. It is patented andis readily repeatable. delivery is simple. the drug stores well inthe typical medical office.
A very well oriented stem company, with technological aspirations well in the realm of reality, extended their bioreactor capabilities just now,two phase two trials to be released in the near future with nice track record behind them.
Cell therapeutics derived from placenta. Proprietary bioreactor. Based in Israel.
needs time and money to develop, but if it is sucsessfull will become a billion + powerhouse.
Seems to be following that pattern set by Mesoblast only with a much smaller market cap.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions